Iron therapy challenges for the treatment of nondialysis CKD patients

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 7, 2016, Pages 1269-1280

  Locatelli, Francesco ^a   Mazzaferro, Sandro ^b   Yee, Jerry ^c  

^a A MANZONI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

Anemia; Chronic; Chronic kidney disease; Erythropoiesis; Ferric Compounds; Humans; Intravenous; Iron; Patient Compliance; Prospective Studies; Renal Insufficiency

Indexed keywords

ANTIANEMIC AGENT; FERRIC CITRATE; FERRIC PYROPHOSPHATE; FERRITIN; FERROUS FUMARATE; FERROUS SULFATE; HEME; HEME IRON POLYPEPTIDE; HEMOGLOBIN; HEPCIDIN; IRON; LIPOSOMAL IRON; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; FERRIC ION; IRON DERIVATIVE; LIPOSOME;

ANEMIA; BLOOD TRANSFUSION; CHRONIC KIDNEY FAILURE; CLINICAL DECISION MAKING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROPOIESIS; HUMAN; IRON ABSORPTION; IRON DEFICIENCY ANEMIA; IRON THERAPY; LOW RISK PATIENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; BLOOD; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANEMIA; FERRIC COMPOUNDS; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; IRON COMPOUNDS; LIPOSOMES; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 85021713498     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00080116     Document Type: Review

References (94)

1. KDIGO: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2: 279-335, 2012
2. Levin A, Rocco M; KDOQI; National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47[Suppl 3]: S11-S145, 2006
3. White CT, Barrett BJ, Madore F, Moist LM, Klarenbach SW, Foley RN, Culleton BF, Tonelli M, Manns BJ; Canadian Society of Nephrology: Clinical practice guidelines for evaluation of anemia. Kidney Int Suppl 74: S4-S6, 2008
4. Madore F, White CT, Foley RN, Barrett BJ, Moist LM, Klarenbach SW, Culleton BF, Tonelli M, Manns BJ; Canadian Society of Nephrology: Clinical practice guidelines for assessment and management of iron deficiency. Kidney Int Suppl 74: S7-S11, 2008
5. Moist LM, Foley RN, Barrett BJ, Madore F, White CT, Klarenbach SW, Culleton BF, Tonelli M, Manns BJ; Canadian Society of Nephrology: Clinical practice guidelines for evidence-based use of erythropoietic-stimulating agents. Kidney Int Suppl 74: S12-S18, 2008
6. Klarenbach SW, Moist LM, Foley RN, Barrett BJ, Madore F, White CT, Culleton BF, Tonelli M, Manns BJ; Canadian Society of Nephrology: Clinical practice guidelines for supplemental therapies and issues. Kidney Int Suppl 74: S19-S24, 2008
7. National Institute for Health and Care Excellence: Anaemia Management in Chronic Kidney Disease-Partial Update, London, National Clinical Guideline Center, Royal College of Physicians, 2015
8. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19[Suppl 2]: ii1-ii47, 2004
9. Schmidt RJ, Dalton CL: Treating anemia of chronic kidney disease in the primary care setting: Cardiovascular outcomes and management recommendations. Osteopath Med Prim Care 1: 14, 2007
10. Phan O, Maillard M, Malluche HH, Stehle JC, Funk F, BurnierM: Effects of sucroferric oxyhydroxide compared to lanthanum carbonate and sevelamer carbonate on phosphate homeostasis and vascular calcifications in a rat model of chronic kidney failure. BioMed Res Int 2015: 515606, 2015
11. Wolf M, White KE: Coupling fibroblast growth factor 23 production and cleavage: Iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 23: 411-419, 2014
12. Macdougall IC, Bircher AJ, Eckardt KU, Obrador GT, Pollock CA, Stenvinkel P, Swinkels DW, Wanner C, Weiss G, Chertow GM; Conference Participants: Ironmanagement in chronic kidney disease:Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 89: 28-39, 2016
13. Theil EC: Ferritin: Structure, gene regulation, and cellular function in animals, plants, and microorganisms. Annu Rev Biochem 56: 289-315, 1987
14. Jacobs A, Miller F, Worwood M, Beamish MR, Wardrop CA: Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. BMJ 4: 206-208, 1972
15. Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang DL, Crooks DR, Sougrat R, Morgenstern A, Galy B, Hentze MW, Lazaro FJ, Rouault TA, Meyron-Holtz EG: Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 116: 1574-1584, 2010
16. Besarab A, Frinak S, Yee J: An indistinct balance: The safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 10: 2029-2043, 1999
17. Vujić M: Molecular basis of HFE-hemochromatosis. Front Pharmacol 5: 42, 2014
18. Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, St Pierre TG, Olynyk JK: Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 6: 77-83, 2011
19. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J: A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60: 2406-2411, 2001
20. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI: Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded betathalassemia/ HbE patients treated with an oral chelator. Blood 104: 1504-1510, 2004
21. Skikne BS, Flowers CH, Cook JD: Serum transferrin receptor:A quantitative measure of tissue iron deficiency. Blood 75: 1870-1876, 1990
22. Babitt JL, Lin HY: Molecular mechanisms of hepcidin regulation:Implications for the anemia of CKD. Am J Kidney Dis 55: 726-741, 2010
23. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M: Immunoassay for human serum hepcidin. Blood 112: 4292-4297, 2008
24. Gaweda AE, Ginzburg YZ, Chait Y, Germain MJ, Aronoff GR, Rachmilewitz E: Iron dosing in kidney disease: Inconsistency of evidence and clinical practice. Nephrol Dial Transplant 30: 187-196, 2015
25. Chung M, Moorthy D, Hadar N, Salvi P, Iovin RC, Lau J: Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease. Comparative Effectiveness Review No. 83. (Prepared by the Tufts Evidence-based Practice Center under Contract No. 290-2007-10055-I.) AHRQ Publication No. 12(13)-EHC140-EF, 2012. Available at: www. effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed August 25, 2015
26. Locatelli F, Del Vecchio L: Haemoglobin levels and healthrelated quality of life: A neglected hard end point. Nephrol Dial Transplant 29: 1272-1274, 2014
27. Cruz MC, Andrade C, Urrutia M, Draibe S, Nogueira-Martins LA, Sesso RC: Quality of life in patients with chronic kidney disease. Clinics (Sao Paulo) 66: 991-995, 2011
28. Finkelstein FO, Story K, Firanek C, Mendelssohn D, Barre P, Takano T, Soroka S, Mujais S: Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 4: 33-38, 2009
29. de Goeij MCM, Meuleman Y, van Dijk S, Grootendorst DC, Dekker FW, Halbesma N; PREPARE-2 Study Group: Haemoglobin levels and health-related quality of life in young and elderly patients on specialized predialysis care. NephrolDial Transplant 29: 1391-1398, 2014
30. Drüeke TB, Locatelli F, Clyne N, Eckardt K-U, Macdougall IC, Tsakiris D, Burger H-U, Scherhag A; CREATE Investigators:Normalization of hemoglobin level in patients with chronic kidney disease and anemia.NEngl J Med 355: 2071-2084, 2006
31. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006
32. Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, de Zeeuw D, Eckardt K-U, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.N Engl J Med 361: 2019-2032, 2009
33. Regidor D, McClellan WM, Kewalramani R, Sharma A, Bradbury BD: Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. Nephrol Dial Transplant 26: 1583-1591, 2011
34. Thamer M, Zhang Y, Kshirsagar O, Cotter DJ, Kaufman JS: Erythropoiesis-stimulating agent use among non-dialysisdependent CKD patients before and after the trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) using a large US health plan database. Am J Kidney Dis 64: 706-713, 2014
35. Miskulin DC, Zhou J, Tangri N, Bandeen-Roche K, Cook C, Ephraim PL, Crews DC, Scialla JJ, Sozio SM, Shafi T, Jaar BG, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators: Trends in anemia management in US hemodialysis patients 2004-2010. BMC Nephrol 14: 264, 2013
36. FDA Drug Safety Communication: Modified Dosing Recommendations to Improve the Safe Use of Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm#hcp Accessed December 14, 2015
37. Evans M, Suttorp MM, Bellocco R, Hoekstra T, Qureshi AR, Dekker FW, Carrero JJ: Trends in haemoglobin, erthyropoietinstimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013 [published online ahead of August 4, 2015]. Nephrol Dial Transplant
38. Hung SC, Kuo KL, Tarng DC, Hsu CC, Wu MS, Huang TP: Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines. Nephrology (Carlton) 19: 735-739, 2014
39. US DOPPS Practice Pattern Monitor: August 2015. Available at:http://www.dopps.org/DPM. Accessed October 26, 2015
40. Fuller DS, Bieber BA, Pisoni RL, Li Y, Morgenstern H, Akizawa T, Jacobson SH, Locatelli F, Port FK, Robinson BM: International comparisons to assess effects of payment and regulatory changes in the United States on Anemia practice in patients on hemodialysis:The Dialysis Outcomes and Practice Patterns Study [published online ahead of print November 18, 2015]. J Am Soc Nephrol doi:ASN.2015060673
41. Fishbane S, Pollack S, Feldman HI, Joffe MM: Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 4: 57-61, 2009
42. Besarab A: Anemia and iron management. Semin Dial 24: 498-503, 2011
43. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH: The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol 1[Suppl 1]: S9-S18, 2006
44. Camaschella C: Iron-deficiency anemia. N Engl J Med 372: 1832-1843, 2015
45. Heath CW, Strauss MB, Castle WB: Quantitative aspects of iron deficiency in hypochromic anemia: (The parenteral administration of iron). J Clin Invest 11: 1293-1312, 1932
46. Hamstra RD, Block MH, Schocket AL: Intravenous iron dextran in clinical medicine. JAMA 243: 1726-1731, 1980
47. Balakrishnan VS, Rao M, Kausz AT, Brenner L, Pereira BJ, Frigo TB, Lewis JM: Physicochemical properties of ferumoxytol, a new intravenous iron preparation. Eur J Clin Invest 39: 489-496, 2009
48. Agarwal R, Vasavada N, Sachs NG, Chase S: Oxidative stress and renal injury with intravenous iron in patientswith chronic kidney disease. Kidney Int 65: 2279-2289, 2004
49. Hayat A: Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res 6: 93-102, 2008
50. Farah M, Crawford RI, Levin A, Chan Yan C: Calciphylaxis in the current era: Emerging ‘ironic’ features? Nephrol Dial Transplant 26: 191-195, 2011
51. Kletzmayr J, Sunder-Plassmann G, Hörl WH: High dose intravenous iron: A note of caution. Nephrol Dial Transplant 17: 962-965, 2002
52. Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40: 90-103, 2002
53. Lim CS, Vaziri ND: Iron and oxidative stress in renal insufficiency. Am J Nephrol 24: 569-575, 2004
54. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N: Induction of protein oxidation by intravenous iron in hemodialysis patients: Role of inflammation. Am J Kidney Dis 40: 1005-1012, 2002
55. Pai AB, Conner T, McQuade CR, Olp J, Hicks P: Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biometals 24: 603-613, 2011
56. Prats M, Font R, García C, Muñoz-Cortés M, Cabré C, Jariod M, Romeu M, Giralt M, Martinez-Vea A: Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients. Clin Nephrol 81: 419-426, 2014
57. Agarwal R, Kusek JW, Pappas MK: A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 88: 905-914, 2015
58. Macdougall IC, Bock AH, Carrera F, Eckardt K-U, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD; FIND-CKD Study Investigators:FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 29: 2075-2084, 2014
59. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD: A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 26: 1599-1607, 2011
60. Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, Thomsen LL, Coyne DW: A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia [published online ahead of print August 6, 2015]. Nephrol Dial Transplant
61. Auerbach M, Ballard H: Clinical use of intravenous iron: Administration, efficacy, and safety. Hematology (Am Soc Hematol Educ Program) 2010: 338-347, 2010
62. Rampton D, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, Patni S, Szebeni J, WeissG: Hypersensitivity reactions to intravenous iron: Guidance for risk minimization and management. Haematologica 99: 1671-1676, 2014
63. European Medicines Agency: New Recommendations to Manage Risk of Allergic Reactions with Intravenous Iron-Containing Medicines. EMA/377372/2013, 2013
64. Sheftel AD, Mason AB, Ponka P: The long history of iron in the Universe and in health and disease. BiochimBiophys Acta 1820: 161-187, 2012
65. Ganz T: Hepcidin and its role in regulating systemic iron metabolism. Hematology (Am Soc Hematol Educ Program) 1: 29-35, 2006
66. Nakanishi T, Hasuike Y, Nanami M, Yahiro M, Kuragano T: Novel iron-containing phosphate binders and anemia treatment in CKD: Oral iron intake revisited [published online ahead of print July 3, 2015]. Nephrol Dial Transplant
67. Geisser P, Burckhardt S: The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 3: 12-33, 2011
68. Hudson JQ, Comstock TJ: Considerations for optimal iron use for anemia due to chronic kidney disease. Clin Ther 23: 1637-1671, 2001
69. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and metaanalysis. Am J Kidney Dis 52: 897-906, 2008
70. Liles AM: Intravenous versus oral iron for treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease. Am J Health Syst Pharm 69: 1206-1211, 2012
71. Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE:Oxidative stress: An essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol Rev 94: 329-354, 2014
72. Kortman GAM, Raffatellu M, Swinkels DW, Tjalsma H: Nutritional iron turned inside out: Intestinal stress froma gut microbial perspective. FEMS Microbiol Rev 38: 1202-1234, 2014
73. Umanath K, Niecestro R, Lewis JB, Dwyer JP: Ferric citrate: A novel phosphate-binding agent. Expert Rev Endocrinol Metab 8: 13-19, 2013
74. Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM: A 12-week, double-blind, placebocontrolled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. Am J Kidney Dis 65: 728-736, 2015
75. Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM; Sucroferric Oxyhydroxide Study Group: Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant 30: 1037-1046, 2015
76. Tran L, Batech M, Rhee CM, Streja E, Kalantar-Zadeh K, Jacobsen SJ, Sim JJ: Serum phosphorus and association with anemia among a large diverse population with and without chronic kidney disease [published online ahead of print August 8, 2015]. Nephrol Dial Transplant
77. Del Vecchio L, Locatelli F: Anemia in chronic kidney disease patients: Treatment recommendations and emerging therapies. Expert Rev Hematol 7: 495-506, 2014
78. Seligman PA, Moore GM, Schleicher RB: Clinical studies of HIP:An oral heme-iron product. Nutr Res 20: 1279-1286, 2000
79. Dull RB, Davis E: Heme iron polypeptide for the management of anaemia of chronic kidney disease. J Clin Pharm Ther 40: 386-390, 2015
80. Nagaraju SP, Cohn A, Akbari A, Davis JL, Zimmerman DL: Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: A randomized controlled trial. BMC Nephrol 14: 64, 2013
81. Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B: Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial. Nephrol Dial Transplant 30: 645-652, 2015
82. Macdougall IC: New anemia therapies: Translating novel strategies from bench to bedside. AmJ KidneyDis 59: 444-451, 2012
83. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic KidneyDisease-Mineral and BoneDisorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009
84. NKF KDOQI: NKF KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Available at: www2.kidney.org/professionals/KDOQI/guidelines_bone/ Guide3.htm. Accessed August 25, 2015
85. Manns BJ, Hodsman A, Zimmerman DL, Mendelssohn DC, Soroka SD, Chan C, Jindal K, Klarenbach S: Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKDMineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 55: 800-812, 2010
86. Goldsmith DJ, Covic A, Fouque D, Locatelli F, Olgaard K, Rodriguez M, Spasovski G, Urena P, Zoccali C, London GM, Vanholder R: Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: A European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant 25: 3823-3831, 2010
87. McMahon LP, Kent AB, Kerr PG, Healy H, Irish AB, Cooper B, Kark A, Roger SD: Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease:A randomized controlled trial. Nephrol Dial Transplant 25: 920-926, 2010
88. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A: A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 26: 445-454, 2006
89. Charytan C, Qunibi W, Bailie GR; Venofer Clinical Studies Group: Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 100: c55-c62, 2005
90. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S; United States Iron Sucrose (Venofer) Clinical Trials Group: A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68: 2846-2856, 2005
91. Aggarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G: Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India 51: 170-174, 2003
92. Stoves J, Inglis H, Newstead CG: A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16: 967-974, 2001
93. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJG: Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19: 1599-1605, 2008
94. Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Block GA: Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 9: 543-552, 2014